| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $33,538,238 | 45 | 100 |
| Moriarty John B | Chief Legal Officer | 0 | $0 | 2 | $252,765 | $-252,765 |
| Calderaro Charles III | Chief Technical Officer | 0 | $0 | 1 | $269,201 | $-269,201 |
| Gallagher Kathleen P. | Chief Program Officer | 0 | $0 | 6 | $599,583 | $-599,583 |
| MacLean Michael F | Chief Financial Officer | 0 | $0 | 4 | $2.04M | $-2.04M |
| McCarthy Teresa | Chief Human Resources Officer | 0 | $0 | 6 | $2.69M | $-2.69M |
| Flanagan W. Michael | Chief Scientific Officer | 0 | $0 | 6 | $3.05M | $-3.05M |
| WILSON TROY EDWARD | director | 0 | $0 | 2 | $3.29M | $-3.29M |
| Hughes Steven George | Chief Medical Officer | 0 | $0 | 8 | $3.36M | $-3.36M |
| LEVIN ARTHUR A | director | 0 | $0 | 2 | $5.25M | $-5.25M |
| Mosbrooker Eric | Chief Commercial Officer | 0 | $0 | 3 | $6.37M | $-6.37M |
| Boyce Sarah | President and CEO | 0 | $0 | 5 | $6.37M | $-6.37M |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Avidity Biosciences, Inc. have bought $0 and sold $33.54M worth of Avidity Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Avidity Biosciences, Inc. have bought $14.4M and sold $19.92M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 800,000 shares for transaction amount of $14.4M was made by RTW INVESTMENTS, LP (10 percent owner) on 2021‑08‑04.
| 2026-01-21 | Sale | Boyce Sarah | President and CEO | 14,387 0.0095% | $72.45 | $1.04M | +0.12% | |
| 2026-01-21 | Sale | McCarthy Teresa | Chief Human Resources Officer | 2,929 0.0019% | $72.45 | $212,206 | +0.12% | |
| 2026-01-21 | Sale | Flanagan W. Michael | Chief Scientific Officer | 6,534 0.0043% | $72.45 | $473,388 | +0.12% | |
| 2026-01-21 | Sale | MacLean Michael F | Chief Financial Officer | 4,542 0.003% | $72.45 | $329,068 | +0.12% | |
| 2026-01-21 | Sale | Hughes Steven George | Chief Medical Officer | 4,895 0.0032% | $72.45 | $354,643 | +0.12% | |
| 2026-01-21 | Sale | LEVIN ARTHUR A | director | 1,758 0.0012% | $72.45 | $127,367 | +0.12% | |
| 2026-01-07 | Sale | Boyce Sarah | President and CEO | 8,576 0.0065% | $72.23 | $619,444 | +0.32% | |
| 2026-01-07 | Sale | McCarthy Teresa | Chief Human Resources Officer | 1,965 0.0015% | $72.23 | $141,932 | +0.32% | |
| 2026-01-07 | Sale | Flanagan W. Michael | Chief Scientific Officer | 2,373 0.0018% | $72.23 | $171,402 | +0.32% | |
| 2026-01-07 | Sale | Moriarty John B | Chief Legal Officer | 2,374 0.0018% | $72.23 | $171,474 | +0.32% | |
| 2026-01-07 | Sale | MacLean Michael F | Chief Financial Officer | 1,974 0.0015% | $72.23 | $142,582 | +0.32% | |
| 2026-01-07 | Sale | Calderaro Charles III | Chief Technical Officer | 3,727 0.0028% | $72.23 | $269,201 | +0.32% | |
| 2026-01-07 | Sale | Hughes Steven George | Chief Medical Officer | 2,373 0.0018% | $72.23 | $171,402 | +0.32% | |
| 2025-10-15 | Sale | McCarthy Teresa | Chief Human Resources Officer | 20,000 0.0154% | $50.15 | $1M | +42.38% | |
| 2025-10-03 | Sale | Mosbrooker Eric | Chief Commercial Officer | 6,562 0.0053% | $45.38 | $297,771 | +52.34% | |
| 2025-09-22 | Sale | Hughes Steven George | Chief Medical Officer | 2,208 0.0016% | $40.58 | $89,601 | +68.97% | |
| 2025-09-15 | Sale | McCarthy Teresa | Chief Human Resources Officer | 15,000 0.012% | $41.41 | $621,143 | +77.40% | |
| 2025-09-15 | Sale | Hughes Steven George | Chief Medical Officer | 1,542 0.0014% | $45.41 | $70,022 | +77.40% | |
| 2025-09-11 | Sale | Flanagan W. Michael | Chief Scientific Officer | 20,000 0.0147% | $38.94 | $778,702 | +73.73% | |
| 2025-09-05 | Sale | Boyce Sarah | President and CEO | 50,000 0.0385% | $49.95 | $2.5M | +41.38% |
| Boyce Sarah | President and CEO | 269007 0.1784% | $19.6M | 0 | 26 | |
| McCarthy Teresa | Chief Human Resources Officer | 113938 0.0756% | $8.3M | 0 | 15 | |
| Flanagan W. Michael | Chief Scientific Officer | 85093 0.0564% | $6.2M | 0 | 14 | |
| Moriarty John B | Chief Legal Officer | 74557 0.0495% | $5.43M | 0 | 2 | |
| MacLean Michael F | Chief Financial Officer | 59290 0.0393% | $4.32M | 0 | 13 | |
| Mosbrooker Eric | Chief Commercial Officer | 55000 0.0365% | $4.01M | 0 | 3 | |
| WILSON TROY EDWARD | director | 54425 0.0361% | $3.97M | 0 | 2 | |
| Gallagher Kathleen P. | Chief Program Officer | 50204 0.0333% | $3.66M | 0 | 9 | |
| Calderaro Charles III | Chief Technical Officer | 49797 0.033% | $3.63M | 0 | 1 | |
| Hughes Steven George | Chief Medical Officer | 31599 0.021% | $2.3M | 0 | 9 | |
| LEVIN ARTHUR A | director | 16562 0.011% | $1.21M | 0 | 30 | |
| RTW INVESTMENTS, LP | 10 percent owner | 4795000 3.1808% | $349.41M | 2 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 2514545 1.668% | $183.23M | 1 | 0 | <0.0001% | |
| Thompson Tamar | director | 0 0% | $0 | 0 | 1 |
$211,610,344 | 91 | 38.45% | $10.55B | |
$2,765,836 | 72 | 20.00% | $11.5B | |
$108,876,545 | 67 | 72.81% | $9.34B | |
$88,307,390 | 38 | -1.70% | $10.11B | |
$19,233,721 | 36 | 70.14% | $11.78B | |
$1,801,511 | 23 | 18.58% | $8.94B | |
$415,090,639 | 19 | -14.04% | $14.5B | |
$11,859,102 | 17 | 18.62% | $8.1B | |
$143,065,458 | 17 | 8.01% | $18.62B | |
$152,272,932 | 16 | -10.78% | $19.36B | |
$1,279,017 | 16 | 51.12% | $9.14B | |
$627,701,115 | 15 | 145.68% | $11.14B | |
$11,898,979 | 10 | 54.58% | $8.02B | |
$284,820 | 10 | 45.67% | $13.06B | |
$948,235 | 8 | 15.56% | $9.38B | |
$41,376,000 | 4 | -12.07% | $7.68B | |
$40,276,273 | 4 | 34.57% | $18.93B | |
Avidity Biosciences, Inc. (RNA) | $36,900,000 | 3 | -9.12% | $10.99B |
$999,989 | 1 | 262.16% | $16.5B |
| Increased Positions | 186 | +77.5% | 33M | +23.41% |
| Decreased Positions | 105 | -43.75% | 10M | -7.23% |
| New Positions | 88 | New | 9M | New |
| Sold Out Positions | 34 | Sold Out | 5M | Sold Out |
| Total Postitions | 321 | +33.75% | 164M | +16.19% |
| Fmr Llc | $1.56M | 14.3% | 21.59M | +5M | +33.36% | 2025-09-30 |
| Janus Henderson Group Plc | $1.05M | 9.62% | 14.52M | +4M | +34.75% | 2025-09-30 |
| Vanguard Group Inc | $953,145.00 | 8.76% | 13.22M | +4M | +42.94% | 2025-09-30 |
| Rtw Investments, Lp | $819,981.00 | 7.53% | 11.37M | +2M | +18.23% | 2025-09-30 |
| Wellington Management Group Llp | $725,700.00 | 6.67% | 10.07M | +815,497 | +8.82% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $705,673.00 | 6.48% | 9.79M | -1M | -9.45% | 2025-09-30 |
| Blackrock, Inc. | $663,506.00 | 6.09% | 9.2M | -134,255 | -1.44% | 2025-09-30 |
| Ra Capital Management, L.P. | $623,018.00 | 5.72% | 8.64M | +1M | +18.92% | 2025-09-30 |
| Avoro Capital Advisors Llc | $551,205.00 | 5.06% | 7.64M | +595,000 | +8.44% | 2025-09-30 |
| State Street Corp | $352,470.00 | 3.24% | 4.89M | +687,123 | +16.35% | 2025-09-30 |